Argenx stock tumbles as plans for Vyvgart in thyroid eye disease cancelled, leading to market celebration.
Stock of Argenx took a significant hit on Monday following the company's decision to halt the development of its lucrative drug, Vyvgart, for treating thyroid eye disease. The unexpected setback for Vyvgart has resulted in a surge for Viridian's stocks. This turn of events has led to a steep decline in Argenx's share prices.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments